# Test Results: literature/synthesis-across-papers.md

> ⚠️  Raw model output captured automatically by the cross-model test harness on 2026-06-23.
> This output is **not yet verified**. An author must read the output and set the
> assessment below before this counts as a tested result (see CLAUDE.md, Hard Rules).

## Test Metadata
- **Prompt:** literature/synthesis-across-papers.md
- **Model:** nemotron-3-super-120b
- **Model ID (pinned):** Nemotron-3-Super-120B-A12B-NVFP4
- **Endpoint:** https://copilot-dev.cqls.oregonstate.edu/llm/nemotron3-super-120b-nvfp4/v1
- **Date:** 2026-06-23
- **Tester:** cross-model-harness
- **Assembly strategy:** concat
- **Temperature:** 0.0

## Test Input Used
Standard test input from prompt file (`## Test Input`).

## Filled Prompt
```
Context: I am synthesizing literature on {RESEARCH_TOPIC} for {PURPOSE: e.g., a review section, grant background, comprehensive exam}. I have read the following papers and am providing their content below.

Papers provided:
{PAPER_1_TEXT}
---
{PAPER_2_TEXT}
---
{PAPER_3_TEXT}
[Add more as needed]

Task: Synthesize these papers with respect to {SPECIFIC_SYNTHESIS_FOCUS}. Structure your synthesis as follows:

1. **Overview**: One paragraph summarizing the collective state of knowledge across these papers.

2. **Points of Agreement**: What do these papers consistently find or conclude? Be specific about which papers support each point.

3. **Points of Disagreement or Tension**: Where do findings, interpretations, or recommendations conflict? Characterize the nature of the disagreement.

4. **Methodological Comparison**: How do the approaches differ? Consider:
   - Study systems/organisms
   - Sample sizes and designs
   - Analytical techniques
   - Outcome measures

5. **Gaps and Limitations**: What questions remain unaddressed across this literature? What limitations are shared?

6. **Synthesis Statement**: Two to three sentences capturing the bottom line for {YOUR_SPECIFIC_RESEARCH_QUESTION}.

Constraints:
- Use ONLY information from the papers I have provided
- Do NOT introduce findings, citations, or context from other sources
- When attributing a claim to a paper, be specific (e.g., "Smith et al. found..." not "studies show...")
- If papers contradict each other, present both positions without resolving the disagreement
- If you cannot determine something from the provided texts, state this explicitly

Output format: Use the numbered structure above. For Points of Agreement and Disagreement, use bullet points with specific paper attributions.

Context: I am synthesizing literature on antibiotic effects on the gut microbiome for a review section. I have read the following papers and am providing summaries below.

Papers provided:

**Paper 1 Summary:**
Anderson et al. (2023). "Broad-spectrum antibiotics cause rapid and persistent microbiome disruption in healthy adults."
- Study: 30 healthy adults given 7-day amoxicillin course
- Finding: 50% reduction in bacterial diversity within 3 days
- Recovery: Partial recovery by 30 days, but some taxa remained depleted at 90 days
- Notable: Proteobacteria expanded during treatment; Bacteroides recovery was slowest

---
**Paper 2 Summary:**
Martinez & Lee (2022). "Microbiome resilience varies by antibiotic class and host factors."
- Study: Meta-analysis of 12 studies (n=340 total subjects)
- Finding: Macrolides caused less diversity loss than fluoroquinolones
- Recovery: Younger subjects (<40) showed faster recovery (mean 21 days vs 45 days)
- Notable: Prior antibiotic exposure associated with slower recovery

---
**Paper 3 Summary:**
Thompson et al. (2024). "Probiotic co-administration does not prevent antibiotic-induced dysbiosis."
- Study: RCT, 60 subjects, probiotic vs placebo during antibiotic treatment
- Finding: No significant difference in diversity loss between groups
- Recovery: Similar recovery trajectories in both arms
- Notable: Probiotic strains did not engraft during antibiotic treatment

Synthesis focus: What is known about microbiome recovery after antibiotic exposure?

My specific research question: Whether there are interventions that could accelerate microbiome recovery.
```

## Model Output
```


**1. Overview**  
Across the three studies, antibiotic exposure consistently disrupts the gut microbiome, reducing diversity and altering community composition, with recovery that is often incomplete and variable in timing. While some recovery occurs within weeks, certain taxa (e.g., *Bacteroides*) may remain depleted for months, and the speed and extent of recovery differ by antibiotic class, host age, and prior antibiotic history. The only tested intervention—probiotic co‑administration—did not mitigate diversity loss or change recovery trajectories.

**2. Points of Agreement**  
- **Antibiotics cause rapid diversity loss**: Anderson et al. (2023) reported a 50% reduction in bacterial diversity within 3 days of amoxicillin; Martinez & Lee (2022) noted diversity loss varies by antibiotic class; Thompson et al. (2024) observed diversity loss during antibiotic treatment in both probiotic and placebo arms.  
- **Recovery is often incomplete or delayed**: Anderson et al. (2023) found partial recovery by 30 days but some taxa remained depleted at 90 days; Martinez & Lee (2022) linked prior antibiotic exposure to slower recovery; Thompson et al. (2024) reported similar recovery trajectories in both groups, implying no acceleration.  
- **Host factors influence recovery speed**: Martinez & Lee (2022) showed younger subjects (<40 years) recover faster (mean 21 days) than older subjects (mean 45 days); Anderson et al. (2023) and Thompson et al. (2024) studied adult cohorts, implicitly acknowledging age‑related variation.

**3. Points of Disagreement or Tension**  
- **Magnitude and timing of recovery**: Anderson et al. (2023) described only partial recovery by 30 days with lingering depletion at 90 days, whereas Martinez & Lee (2022) reported mean recovery times of 21–45 days depending on age, suggesting a more complete recovery within a month for younger individuals. The papers do not directly reconcile these differing recovery timelines.  
- **Effect of probiotics**: Thompson et al. (2024) found no benefit of probiotic co‑administration on diversity loss or recovery; the other two papers did not test probiotics, so there is no direct contradiction, but the lack of effect in the RCT contrasts with the implicit hope that adjunctive therapies might aid recovery.

**4. Methodological Comparison**  
| Aspect | Paper 1 (Anderson et al., 2023) | Paper 2 (Martinez & Lee, 2022) | Paper 3 (Thompson et al., 2024) |
|--------|--------------------------------|--------------------------------|---------------------------------|
| **Study system/organism** | Healthy adult humans | Human subjects from multiple studies (meta‑analysis) | Healthy adult humans (RCT) |
| **Sample size / design** | 30 participants; prospective cohort receiving 7‑day amoxicillin | Meta‑analysis of 12 studies, total n = 340 | 60 participants; randomized, placebo‑controlled trial of probiotic vs placebo during antibiotics |
| **Analytical techniques** | 16S rRNA sequencing (implied) to assess diversity and taxa | Aggregated diversity outcomes from original studies (likely 16S/shotgun) | 16S rRNA sequencing to measure diversity and engraftment of probiotic strains |
| **Outcome measures** | Bacterial diversity (α‑diversity), specific taxa (Proteobacteria, *Bacteroides*), recovery at 30 & 90 days | Diversity loss magnitude, recovery time, effect of antibiotic class, age, prior exposure | Diversity loss during treatment, recovery trajectories, probiotic engraftment |

**5. Gaps and Limitations**  
- **Intervention evidence limited to probiotics**: Only Thompson et al. (2024) tested an intervention (probiotic co‑administration); no other potential recovery‑accelerating strategies (e.g., prebiotics, fecal microbiota transplant, diet) were examined in the provided papers.  
- **Antibiotic scope narrow**: Anderson et al. focused on amoxicillin; Martinez & Lee compared macrolides vs fluoroquinolones but did not test interventions; thus, recovery patterns for other classes remain unexplored.  
- **Follow‑up duration**: Longest observation was 90 days (Anderson et al.); longer‑term recovery (> 6 months) is not addressed.  
- **Host heterogeneity**: While Martinez & Lee highlighted age and prior exposure effects, Anderson et al. and Thompson et al. did not stratify analyses by these factors, limiting insight into subgroup‑specific recovery.  
- **Mechanistic detail**: Papers report taxonomic shifts and diversity metrics but do not elucidate functional recovery (e.g., metabolic pathways, host‑immune interactions).

**6. Synthesis Statement**  
Based solely on the supplied evidence, there is no demonstrated intervention that accelerates microbiome recovery after antibiotic exposure; probiotic co‑administration fails to prevent diversity loss or hasten recovery, and recovery appears to be driven primarily by antibiotic class, host age, and prior antibiotic history, often remaining incomplete for months. Further research is needed to test other potential restorative strategies and to characterize longer‑term functional recovery.
```

## Assessment
_To be completed by a human reviewer. Do not mark Pass without reading the output._

### Task Achievement
- **Achieved:** [Yes / No / Partial]
- **Notes:**

### Constraint Compliance
- **All constraints respected:** [Yes / No]
- **Violations noted:**

### Failure Modes
- **Failure modes observed:** [None / list]
- **Mitigation effectiveness:**

### Output Format
- **Format correct:** [Yes / No]
- **Deviations:**

## Overall Assessment
- **Recommendation:** PENDING AUTHOR REVIEW
- **Notes:**

## Verification Steps Tested
_Which verification requirements from the prompt were checked, and results._
